Abstract: A class of multiphase rubidium titanate functional ceramic materials is provided in this disclosure, the composition of which comprises phases of rubidium n-titanates with chemical formula of Rb2TinO2n+1, that of titanium dioxide with chemical formula of TiO2, and a small amount of optional dopant for the purpose of further improving or adjusting performance of the materials. The said materials are obtained by mixing the sources of rubidium, titanium and optional dopant to get a highly active fine-powdery precursor, and then by making heat-treatment in air of the precursor. The said materials possess unusual electrical and electrochemical properties, such as colossal permittivity up to the order of 109 at room temperature accompanied by relatively low dielectric loss, excellent insulativity accompanied by high ionic conductivity up to 10?3 S/cm, have a broad application prospect in the fields like rechargeable high energy density storage devices, semiconductor devices and catalytic purification.

Abstract: The present disclosure relates to an unmanned lane keeping method and device, a computer device, and a storage medium. The method includes that: a vehicle road image collected by a data collector of the vehicle is received; the vehicle road image is transmitted to a preset DNN model of the vehicle for processing to obtain a steering wheel angle corresponding to the vehicle road image, wherein the DNN model of the vehicle is established by deep learning, and is used for characterizing a correspondence between the vehicle road image and the steering wheel angle; and the vehicle is controlled to keep driving in a corresponding lane according to the steering wheel angle.

Abstract: The present disclosure relates to an unmanned lane keeping method and device, a computer device, and a storage medium. The method includes that: a vehicle road image collected by a data collector of the vehicle is received; the vehicle road image is transmitted to a preset DNN model of the vehicle for processing to obtain a steering wheel angle corresponding to the vehicle road image, wherein the DNN model of the vehicle is established by deep learning, and is used for characterizing a correspondence between the vehicle road image and the steering wheel angle; and the vehicle is controlled to keep driving in a corresponding lane according to the steering wheel angle.

Abstract: Provided are a path planning method and device for an unmanned vehicle, road segments of an origin and destination of a path are acquired; path search is performed to generate an initial path according to an exit endpoint of the road segment where the origin is located, an entrance endpoint of the road segment where the destination is located, and entrance endpoints and exit endpoints of the road segments for connecting the exit endpoint of the road, segment where the origin is located to the entrance endpoint of the road segment where the destination is located; an exit endpoint of a previous road section of the connecting passages in a passable direction is updated according to entrance endpoints of the connecting passages in the initial path; and a final planed path is generated according to different endpoints in the updated initial path.

Abstract: Various embodiments of the invention include a motor system for driving a swing and controlling the speed and/or amplitude of the swing. In one embodiment, the motor system includes a DC motor, a swing velocity sensor system, and a swing velocity control circuit. The DC motor drives the swing through at least one fill swing cycle, and then the motor is allowed to free-wheel for at least a half swing cycle. During the free-wheeling half cycle, the swing velocity sensor system measures the velocity of the swing and compares the measured velocity to a goal velocity. The control circuit increases or decreases the velocity depending on this comparison. In other embodiments, the system includes a swing amplitude sensor system that measures the amplitude of the swing and a swing amplitude control circuit that compares the measured amplitude to a goal amplitude.

Abstract: Various embodiments of the invention include a motor system for driving a swing and controlling the speed and/or amplitude of the swing. In one embodiment, the motor system includes a DC motor, a swing velocity sensor system, and a swing velocity control circuit. The DC motor drives the swing through at least one fill swing cycle, and then the motor is allowed to free-wheel for at least a half swing cycle. During the free-wheeling half cycle, the swing velocity sensor system measures the velocity of the swing and compares the measured velocity to a goal velocity. The control circuit increases or decreases the velocity depending on this comparison. In other embodiments, the system includes a swing amplitude sensor system that measures the amplitude of the swing and a swing amplitude control circuit that compares the measured amplitude to a goal amplitude.

Abstract: Substituted dihydrophthalazine sulfur containing compositions are provided which are active as non-NMDA ionotropic excitatory amino acid (EAA) receptor antagonists. The compositions are useful for treating disorders associated with excessive activation of the non-NMDA subtype of the ionotropic EAA receptor. The compounds further are useful as testing agents to identify and characterize other compounds for the treatment of these disorders. The compounds are useful therapeutically as sedatives or for the treatment of neuropsychopharmacological disorders such as stroke, ischemia and epilepsy. The compositions may be provided in combination with a suitable carrier for oral or parenteral administration. The compounds may be administered orally or parenterally for the treatment of a variety of disorders associated with non-NMDA EEA receptor function.

Abstract: Substituted benzodiazepine compositions are provided which are active as non-NMDA ionotropic excitatory amino acid (EAA) receptor antagonists. The compounds are generally 7- or 8-mono substituted 5H-2,3-benzodiazepines. The compositions are useful for treating disorders associated with excessive activation of the non-NMDA subtype of the ionotropic EAA receptor. The compounds further are useful as testing agents to identify and characterize other compounds for the treatment of these disorders. The compounds are useful therapeutically as sedatives or for the treatment of neurosychopharmacological disorders such as stroke, ischemia and epilepsy. The compositions may be provided in combination with a suitable carrier for oral or parenteral administration. The compounds may be administered orally or parenterally for the treatment of a variety of disorders associated with non-NMDA EEA receptor function.

Abstract: Substituted dihydrophthalazine sulfur containing compositions are provided which are active as non-NMDA ionotropic excitatory amino acid (EAA) receptor antagonists. The compositions are useful for treating disorders associated with excessive activation of the non-NMDA subtype of the ionotropic EAA receptor. The compounds further are useful as testing agents to identify and characterize other compounds for the treatment of these disorders. The compounds are useful therapeutically as sedatives or for the treatment of neurosychopharmacological disorders such as stroke, ischemia and epilepsy. The compositions may be provided in combination with a suitable carrier for oral or parenteral administration. The compounds may be administered orally or parenterally for the treatment of a variety of disorders associated with non-NMDA EEA receptor function.

Abstract: Substituted dihydrophthalazine sulfur containing compositions are provided which are active as non-NMDA ionotropic excitatory amino acid (EAA) receptor antagonists. The compositions are useful for treating disorders associated with excessive activation of the non-NMDA subtype of the ionotropic EAA receptor. The compounds further are useful as testing agents to identify and characterize other compounds for the treatment of these disorders. The compounds are useful therapeutically as sedatives or for the treatment of neurosychopharmacological disorders such as stroke, ischemia and epilepsy. The compositions may be provided in combination with a suitable carrier for oral or parenteral administration. The compounds may be administered orally or parenterally for the treatment of a variety of disorders associated with non-NMDA EEA receptor function.

Abstract: Disclosed is a method for inhibiting, stimulating, modulating, or regulating glutamate reuptake. The method makes use of compounds that are ligands of glutamate receptors, including many agonists, or antagonists of glutamate receptors. It has been discovered that such compounds can bind to or modulate glutamate transporters and affect extracellular glutamate levels by affecting transporter activity. The disclosed compounds can have a variety of effects on glutamate transporter activity including activation or inhibition. Such compounds are useful to treat various neurological diseases and conditions involving glutamate transporter and glutamate receptor activation. For example, excess extracellular glutamate is a cause of excessive activation of glutamate receptors. Stimulating glutamate reuptake by glutamate transporters can ameliorate excessive activation of glutamate receptors by reducing the extracellular glutamate concentration. Prodrug forms of transporter compounds can be used as drugs.

Abstract: Disclosed are prodrug compounds of a class of alkyl carboxy amino acid analogs of glutamic acid that act as specific regulators of the kainate EAA receptor cation channel. These compounds are useful for treating neurological, neuropsychological, neuropsychiatric, neurodegenerative, neuropsychopharmacological and functional disorders associated with excessive or insufficient activation of the kainate subtype of the ionotropic EAA receptors; treating cognitive disorders associated with deactivation, suboptimal activation or over-activation of the kainate receptor; alleviating pain and improving and enhancing memory, learning, and associated mental processes.

Abstract: Substituted benzodiazepine compositions are provided which are active as non-NMDA ionotropic excitatory amino acid (EAA) receptor antagonists. The compounds are generally 7- or 8-mono substituted 5H-2,3-benzodiazepines. The compositions are useful for treating disorders associated with excessive activation of the non-NMDA subtype of the ionotropic EAA receptor. The compounds further are useful as testing agents to identify and characterize other compounds for the treatment of these disorders. The compounds are useful therapeutically as sedatives or for the treatment of neurosychopharmacological disorders such as stroke, ischemia and epilepsy. The compositions may be provided in combination with a suitable carrier for oral or parenteral administration. The compounds may be administered orally or parenterally for the treatment of a variety of disorders associated with non-NMDA EEA receptor function.

Abstract: Substituted dihydrophthalazine sulfur containing compositions are provided which are active as non-NMDA ionotropic excitatory amino acid (EAA) receptor antagonists. The compositions are useful for treating disorders associated with excessive activation of the non-NMDA subtype of the ionotropic EAA receptor. The compounds further are useful as testing agents to identify and characterize other compounds for the treatment of these disorders. The compounds are useful therapeutically as sedatives or for the treatment of neurosychopharmacological disorders such as stroke, ischemia and epilepsy. The compositions may be provided in combination with a suitable carrier for oral or parenteral administration. The compounds may be administered orally or parenterally for the treatment of a variety of disorders associated with non-NMDA EEA receptor function.